Walk into any gym subculture forum, longevity Discord, or bodybuilding subreddit and you will find people discussing peptides with confident specificity: which compound helps tendon healing, which one blocks appetite, which one tans your skin, which one releases growth hormone. They are trading information about a class of molecules that is almost entirely outside the regulated medical system.
These are grey-market peptides — sometimes called research chemicals, sometimes called investigational peptides, often just called “peps.” They are real biochemistry, with real science behind them, wrapped in a regulatory and commercial environment that produces a lot of confusion and a lot of risk.
This article is an attempt to give a level-headed, science-first view of the category. Not a list of what to buy. Not dosing. Not a supplier directory. Just what is actually known, what is not known, and why the gap between those two is bigger than most users assume.
What “grey market” really means
In the United States regulatory landscape, drugs fall into a few categories:
- FDA-approved drugs. Tested in randomized controlled trials, reviewed by the FDA, labeled for specific indications, prescribed by physicians.
- Dietary supplements. Governed by DSHEA; cannot make disease claims; limited pre-market testing.
- Controlled substances. Scheduled by the DEA; possession and distribution are criminally regulated.
Grey-market peptides sit outside all three. They are not FDA-approved. They are generally not marketed as supplements (they are not ingredients in food). They are not DEA-scheduled as controlled substances. They are sold as research chemicals — products for laboratory research, explicitly labeled “not for human consumption.” That labeling is what keeps the products on the market, and it is why users are simultaneously the primary customers and, legally speaking, not the intended customers.
The practical consequences of this in-between status:
- No required manufacturing quality control or GMP standards
- No required purity, potency, or endotoxin testing
- No required sterile fill-finish if the product will be injected
- No required labeling standards for concentration or identity
- No recourse if something goes wrong
The common grey-market peptides
The specific molecules that dominate this conversation are not fringe. Most of them have been studied in peer-reviewed literature. Their problems are regulatory and translational, not fundamentally about the chemistry being unknown.
BPC-157 (Body Protection Compound)
A 15-residue synthetic peptide derived from a gastric protein. The preclinical literature focuses on wound healing, tendon repair, and gastrointestinal protection in rodents. Human evidence is sparse. FDA-unapproved. WADA-prohibited since 2022. We cover it in more depth in our BPC-157 research guide.
TB-500 / Thymosin beta-4 fragment
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring actin-binding protein involved in cell migration and tissue repair. Most preclinical data concerns wound healing and cardiac repair. It is commonly discussed alongside BPC-157 in the injury-recovery context. Not FDA-approved for human use.
Melanotan II
A synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Binds multiple melanocortin receptors, producing skin tanning and appetite/libido effects. Grey-market use is long-standing but concerning: dermatologists have reported changes in existing nevi and rare cases of melanoma in users, and the non-selective receptor binding profile produces many other off-target effects. Not FDA-approved.
CJC-1295 and Ipamorelin (growth hormone secretagogues)
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed for extended half-life. Ipamorelin is a selective ghrelin receptor agonist that stimulates growth hormone release without significant effects on cortisol or prolactin. They are frequently used together in grey-market protocols targeting endogenous growth hormone release. Both are captured under the WADA Prohibited List in the peptide hormones and growth factors category. Not FDA-approved for general human use.
Others in the category
Additional peptides that commonly appear in grey-market channels include PT-141 (bremelanotide — notable exception, it has an FDA-approved form for a specific indication but much of the grey-market use is off-label), MOTS-c, Epitalon, SS-31, and various GHK-Cu preparations. Each has its own research context and its own regulatory standing; none should be assumed to be equivalent to the others.
The animal-to-human evidence gap
Almost every grey-market peptide is supported primarily by preclinical studies — cell culture experiments, rodent models, the occasional larger animal. This is how serious drug development starts. It is not how serious drug development ends. The path from a rodent study to an approved drug routinely takes a decade and billions of dollars because the translational gap is real.
Several specific ways that gap tends to bite:
- Dose translation. Rodent doses in published studies are frequently much higher on a mg/kg basis than what human users self-administer. Efficacy seen at one dose cannot be assumed at another.
- Species-specific biology. Wound healing, metabolism, and immune responses differ in meaningful ways between rodents and humans. A peptide that does something in one can do nothing, or something different, in the other.
- Controlled vs real-world conditions. Laboratory studies use defined injury models, defined diets, and defined timing. Real-world users have none of those controls.
- Publication bias. Positive findings get published; null findings often do not. The signal in the literature may be stronger than the true signal.
- Single-lab findings. Some grey-market peptides — BPC-157 is the canonical example — have research literatures dominated by a small number of groups. Independent replication is the gold standard of science for good reason.
Sourcing risks
Even if you set the translational question aside entirely, the sourcing problem remains. A vial of grey-market peptide is not a pharmaceutical. It is a product made somewhere, by someone, to standards you cannot verify, shipped through channels with no accountability.
Documented problems in the grey-market peptide ecosystem include:
- Incorrect identity. Mass spectrometry studies of products from some vendors have found that the actual peptide does not match the label.
- Incorrect concentration. Labeled mg/vial frequently does not match actual content.
- Contamination. Including bacterial endotoxin, which produces systemic inflammatory responses when injected, and trace solvents or metals from synthesis.
- Degradation. Peptides are sensitive to temperature, pH, and time. Shipping and storage failures can leave you with fragments instead of full-length molecules.
- Sterility failures. Injectable products that have not been sterile-fill-finished can introduce infection at the injection site or systemically.
None of these are hypothetical. They are all real failure modes that have been observed in various investigations of grey-market peptide products. For an individual buyer, the brand-new vial in front of you is essentially a single data point with an unknowable denominator.
Intersections with WADA and competitive sport
The World Anti-Doping Agency maintains a Prohibited List that covers many peptides relevant to the grey-market scene: growth hormone releasing peptides, IGF-1 analogs, BPC-157 and similar non-approved substances, SARMs (which are often grouped with the peptide scene culturally), and more. Any athlete subject to WADA testing should assume that a given grey-market peptide is banned unless they have specifically verified otherwise.
This intersection matters beyond professional athletes. Many amateur and collegiate athletes, and any athlete in a WADA-aligned federation, are subject to the same rules. A positive test for a grey-market peptide can end a career.
Responsible research framing
It is possible to be genuinely curious about this class of molecules without endorsing their unregulated use. A responsible research posture looks roughly like this:
- Read the primary literature. Not forum posts. Not vendor websites. Actual peer-reviewed papers, with attention to study size, controls, and who funded the work.
- Distinguish hypothesis from conclusion. “X improved wound healing in rats” is not the same as “X improves wound healing in humans.”
- Separate mechanism stories from outcomes data. A plausible mechanism does not guarantee a clinical benefit.
- Take regulatory signals seriously. The FDA is sometimes wrong, but the absence of approval after decades of availability is a meaningful signal about where the evidence stands.
- Use computational tools. You can learn a great deal about a peptide's sequence, structure, charge, and predicted properties without ever touching a vial.
That last point is where Peptide Lab fits in. The workspaces for BPC-157, TB-500, Melanotan II, and the other grey-market peptides in the library are explicitly educational. You can view the sequence, run ESMFold, explore mutations, and compare variants — the same kind of analysis a computational chemist would do in a research setting — without any suggestion that you should inject anything.
Bottom line
Grey-market peptides are a real phenomenon, backed by real but limited science, sold through unregulated channels, and used in ways that outrun the evidence base. The biology is genuinely interesting. The commercial ecosystem around the biology is genuinely dangerous. Both things are true at the same time.
The best things an informed reader can do are: understand the molecules at the level of sequence and mechanism, respect the gap between animal and human evidence, recognize the sourcing risks, and — if they have questions about any health condition — talk to a licensed clinician, not a Discord server.